All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 26, 2023
Home » Topics » Disease categories and therapies » Endocrine/Metabolic

Endocrine/Metabolic
Endocrine/Metabolic RSS Feed RSS

Endocrine/Metabolic

Gilead Sciences describes new GLP-1R agonists

Nov. 18, 2022
No Comments
Gilead Sciences Inc. has synthesized carboxy-benzimidazoles acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of arthritis, diabetes, eating disorders, macular degeneration, myocardial infarction, nonalcoholic steatohepatitis, sleep apnea and Parkinson's disease, among others.
Read More
Pancreas illustration
Endocrine/Metabolic

Novel activators of AMPK show efficacy in models of type 2 diabetes

Nov. 16, 2022
No Comments
Researchers from Rigel Pharmaceuticals Inc. have reported the discovery of indirect activators of AMPK as potential candidates for the treatment of type 2 diabetes.
Read More
Obesity, fat cell research concept image
Endocrine/Metabolic

Rose Biosciences to take forward MCW discovery for obesity

Nov. 15, 2022
No Comments
Medical College of Wisconsin (MCW) has announced the founding of Rose Biosciences, a biotech company pioneering a new approach to obesity treatment based on a discovery at MCW.
Read More
Mitochondria long way from the nucleus and in need of closer sources of proteins
Neurology/Psychiatric

Neuroscience 2022: ‘Strawberries’, ‘cabbages,’ fats in neuronal mitochondria

Nov. 15, 2022
By Mar de Miguel
No Comments
Neurons are specialized cells with a high metabolic demand to fulfill their function, survive or keep a healthy half-life. In this sense, the anabolism and catabolism of proteins and lipids could be associated to different neurodegenerative diseases. At the 2022 annual meeting of the Society for Neuroscience, scientists reported the latest discoveries on neuron metabolic needs at a session on 'Powering Thoughts: The Regulation of Neuronal Energy Metabolism and Mitochondria.'
Read More

Ardelyx’s tenapanor follows rocky row to US adcom

Nov. 14, 2022
By Mari Serebrov
No Comments
Ardelyx Inc. could have a rocky row to hoe when it makes its case for tenapanor, as a hyperphosphatemia therapy in adults with chronic kidney disease, before the U.S. FDA’s Cardiovascular and Renal Drugs Advisory Committee Nov. 16. The big question facing the adcom is whether the change in baseline serum phosphorous levels achieved by the drug is clinically meaningful. Clearly, FDA reviewers don’t think so, as that question already has resulted in delayed PDUFA dates, a complete response letter and two formal dispute resolution requests.
Read More
Cancer research illustration
Cancer

From mouse to man, UBR2 is target in cancer cachexia

Nov. 14, 2022
By W. Todd Penberthy
No Comments
Investigators working at University of Texas Health Science Center, Houston, have discovered that the ubiquitin ligase UBR2 is up-regulated and sufficient for targeting the myosin heavy chain protein for the degradation characteristic of cancer cachexia. UBR2 knockout or pharmacological inhibition could prevent cachexia in mice. Confirmatory observations were noted in cancer cachexia patient-derived tissues.
Read More
Endocrine/Metabolic

Novartis discovers new GLP-1 receptor agonists for obesity

Nov. 11, 2022
No Comments
Novartis AG has described novel imidazole derivatives acting as activators of the GLP-1 receptor for the treatment of obesity.
Read More
Brain with handshake and cityscape

Minoryx, Neuraxpharm enter pact on European rights to leriglitazone

Nov. 10, 2022
By Cormac Sheridan
No Comments
Minoryx Therapeutics SL is banking what it described as “a significant double-digit up-front payment” and could earn up to €258 million (US$262.1 million) more in milestone payments and development funding from a license agreement with Neuraxpharm GmbH, which covers European rights to its lead drug candidate, leriglitazone, in central nervous system indications. It will also receive tiered double-digit royalties on product sales.
Read More
Concept art for blood sugar.
Endocrine/Metabolic

Zealand Pharma presents preclinical data on GIP analogue ZP-6590

Nov. 9, 2022
No Comments
Researchers from Zealand Pharma A/S have presented details on their investigation of ZP-6590 as an antiobesity and antiemetic drug in mice.
Read More
Cholesterol plaque in artery

Innovent bolsters case for hypercholesterolemia MAb with phase III results

Nov. 8, 2022
By David Ho
No Comments
Innovent Biologics Inc. said that, compared to a placebo, both doses of its anti-PCSK-9 monoclonal antibody tafolecimab tested in a phase III trial “yielded significant and durable reductions” in low-density lipoprotein cholesterol levels and showed a favorable safety profile in Chinese patients with non-familial hypercholesterolemia.
Read More
Previous 1 2 … 5 6 7 8 9 10 11 12 13 … 1731 1732 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 24, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 24, 2022.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Pfizer-Seagen logos on puzzle pieces

    Pfizer to buy Seagen for $43B

    BioWorld
    Pfizer Inc.’s appetite for acquisitions shows no signs of abating as it announced this morning its plan to acquire biotech Seagen Inc. for a whopping $43 billion...
  • In war against T1D onset, Tzield-bearer Provention’s comrade Sanofi plans $2.9B takeover

    BioWorld
    Shares of Provention Bio Inc. (NASDAQ:PRVB) closed March 13 at $24.10, up $17.40, or 259%, after Wall Street learned that collaborator Sanofi SA intends to...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing